Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In...

Area of Science:

• Oncology
• Radiation Oncology
• Molecular Biology

Background:

• Radiation therapy planning for metastatic non-small cell lung cancer (NSCLC) currently does not incorporate driver gene mutations.
• Epidermal growth factor receptor (EGFR) mutations are key drivers in some NSCLC cases.
• Understanding radiosensitivity based on EGFR mutation status is crucial for personalized treatment.

Purpose of the Study:

• To compare the radiosensitivity of non-small cell lung cancer (NSCLC) with and without EGFR driver gene mutations.
• To evaluate the clinical efficacy of radiotherapy in NSCLC patients with and without EGFR mutations.
• To investigate the in vitro radiosensitivity of NSCLC cell lines based on EGFR mutation status.

Main Methods:

• Clinical analysis of 42 metastatic NSCLC patients undergoing whole-brain radiotherapy, comparing cranial control rates between EGFR mutation-positive (13 patients) and negative groups using Kaplan-Meier analysis.
• In vitro study involving colony formation assays and DNA double-strand break assessments in five NSCLC cell lines (2 EGFR-negative, 3 EGFR-positive) after irradiation (0-8 Gy).

Main Results:

• EGFR mutation-positive NSCLC patients demonstrated significantly higher cranial control rates compared to EGFR mutation-negative patients (p=0.021).
• In vitro, EGFR mutation-positive NSCLC cells exhibited significantly reduced colony formation after 2 Gy and 4 Gy irradiation (p=0.002).
• EGFR mutation-positive cells showed significantly increased DNA double-strand breaks 24 hours post-irradiation (p<0.001).

Conclusions:

• Both clinical and in vitro findings indicate that non-small cell lung cancer (NSCLC) with EGFR mutations is more sensitive to radiation.
• EGFR mutation status is a potential predictive biomarker for radiotherapy response in NSCLC.
• This suggests a potential role for tailoring radiation parameters based on EGFR mutation status in NSCLC treatment.